Current status in cancer cell reprogramming and its clinical implications

Izgi, Kenan; CANATAN, HALİT; Iskender, Banu

doi:10.1007/s00432-016-2258-5

Current status in cancer cell reprogramming and its clinical implications

Atıf İçin Kopyala

Izgi K., CANATAN H., Iskender B.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, cilt.143, sa.3, ss.371-383, 2017 (SCI-Expanded)

Yayın Türü: Makale / Derleme
Cilt numarası: 143 Sayı: 3
Basım Tarihi: 2017
Doi Numarası: 10.1007/s00432-016-2258-5
Dergi Adı: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.371-383
Erciyes Üniversitesi Adresli: Evet

Özet

The technology of reprogramming a terminally differentiated cell to an embryonic-like state uncovered the possibility of reprogramming a malignant cell back to a more manageable stem cell-like state. Since the current cancer models suffer from reflecting heterogeneous tumour structure and limited to express the late-stage markers, the induced pluripotent stem cell (iPSC) technology could provide an alternative model to recapitulate the early stages of cancer. Generation of iPSCs from cancer cells could offer a tool for understanding the mechanisms of tumour initiation-progression in vitro, a platform for studying tumour heterogeneity and origin of cancer stem cells and a source for cancer type-specific drug discovery studies.